Test Price
4,800 AED✅ Home Collection Available
Glioma Panel (MGMT, IDH1&2, FISH 1p19q) – Molecular Subtyping for Diffuse Gliomas
Executive Summary & Core Metrics
Clinical Summary: The Glioma Panel simultaneously evaluates MGMT promoter methylation, IDH1/2 hotspot mutations, and chromosome 1p/19q codeletion — three biomarkers essential for current WHO classification of diffuse gliomas. Price: 4,800 AED. Turnaround: 14–21 calendar days. Methodology: MLPA + FISH + Sanger Sequencing (three-platform integrated). Specimen: Tumour tissue (biopsy or surgical resection). Hospital extraction only. Insurance verification: +971 54 548 8731 (WhatsApp). Corporate oversight by DNA Labs UAE, DHA Licensed Facility No. 1143, Dubai Healthcare City.
Test Overview & Methodology
This integrated molecular panel delivers three definitive results from a single tumour specimen: MGMT promoter methylation status (predictive of temozolomide response), IDH1/2 mutation analysis (prognostic and diagnostic for lower-grade gliomas), and 1p/19q codeletion detection by FISH (diagnostic marker for oligodendroglioma). The three-platform approach — MLPA for quantitative methylation, FISH for chromosomal loss, and Sanger sequencing for point mutations — ensures analytical sensitivity exceeding 99% for each target. Results are reported in a clinically actionable format with expert interpretation by a board-certified radiologist and a consultant medical geneticist.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Methodology | MLPA + FISH + Sanger Sequencing (three‑platform integrated) | Single‑gene PCR or NGS without methylation profiling |
| Analytical Sensitivity | ≥99% for methylation, mutations, and codeletion | Variable; often lacks quantitative methylation assessment |
| Turnaround Time | 14–21 calendar days | Typically 3–4 weeks if sent overseas |
| Regulatory Compliance | DHA/MOHAP registered, ISO 9001:2015, UAE PDPL | May not meet UAE genetic data requirements |
Physician Insight & Safety Protocols
“This three-biomarker panel enables precise glioma subtyping that directly informs prognosis and treatment planning. MGMT methylation status guides temozolomide prescribing, IDH1/2 mutation status refines diagnosis and risk stratification, and 1p/19q codeletion confirms oligodendroglial lineage. Clinicians must correlate all molecular findings with histopathology and contrast-enhanced MRI. The test is a powerful decision-support tool and must be interpreted within the full clinical context.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Advisory: Medication Continuation
Do not discontinue any prescribed therapy without direct consultation with your treating physician.
Abrupt cessation of corticosteroids, antiepileptics, or chemotherapy agents can precipitate serious adverse events including rebound oedema, seizure recurrence, or tumour progression. Always discuss test results and medication adjustments with your clinical team.
Exclusion Criteria & Emergency Red Flags
- Active systemic or local infection at the proposed biopsy or surgical site — defer sampling until infection is cleared.
- Inability to safely obtain an adequate tumour tissue specimen (biopsy or surgical resection is mandatory).
- Unstable medical status (e.g., uncontrolled hypertension, coagulopathy) contraindicating tissue acquisition.
- Emergency red flags: New-onset seizures, sudden neurological decline, signs of raised intracranial pressure (projectile vomiting, blurred vision, severe morning headache) — seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. Why is MGMT methylation testing performed in glioma?
Answer: MGMT promoter methylation is a strong predictor of response to temozolomide chemotherapy and correlates with prolonged overall survival in glioblastoma patients. Methylation silencing of the MGMT DNA repair gene renders tumour cells more vulnerable to alkylating agents.
2. How reliable is FISH for 1p/19q codeletion analysis?
Answer: FISH remains the reference standard for detecting 1p/19q codeletion in clinical practice. It delivers rapid, quantitative results with high specificity for oligodendroglioma diagnosis. Our laboratory uses dual-colour probe sets and a validated scoring protocol to ensure accuracy.
3. How is the tumour tissue specimen collected for this panel?
Answer: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. A neurosurgeon or interventional radiologist obtains the specimen via stereotactic biopsy or open surgical resection under sterile conditions.
4. Can I receive genetic counselling before and after the test?
Answer: Yes. Our consultant medical geneticist, Ms. Lina Osama Zaki Quteineh (DHA ID: 9294403), provides pre-test counselling on the implications of germline and somatic findings, as well as post-test results interpretation. A referral from your treating neurologist or oncologist is recommended.
UAE Regulatory & Data Privacy Adherence
Compliance Framework
All genetic testing at DNA Labs UAE is conducted under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent, data minimisation, and purpose limitation are enforced at every stage. Clinical safety and informed consent for invasive specimen collection comply with Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and holds DHA/MOHAP facility licensure. Direct billing verification is available via WhatsApp at +971 54 548 8731.
Clinical & Logistical Metadata
| Test Name | Glioma Panel (MGMT Promoter Methylation, IDH1/2 Mutations, FISH 1p/19q Codeletion) |
| Price (AED) | 4,800 |
| Turnaround Time | 14–21 calendar days |
| Sample Type / Matrix | Tumour tissue (biopsy or surgical resection) — Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. |
| Methodology Used | MLPA (methylation) + FISH (1p/19q) + Sanger Sequencing (IDH1/2) |
| ICD-10-CM Code | C71.9, D43.2 |
| LOINC Code | 92011-4 |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians